<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03003325</url>
  </required_header>
  <id_info>
    <org_study_id>Low-PV</org_study_id>
    <nct_id>NCT03003325</nct_id>
  </id_info>
  <brief_title>The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV</brief_title>
  <acronym>Low-PV</acronym>
  <official_title>The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione per la Ricerca Ospedale Maggiore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AOP Orphan Pharmaceuticals AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione per la Ricerca Ospedale Maggiore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Low-PV study is a multicenter, phase II, randomized trial aimed to assess whether the&#xD;
      addition of Pegylated Proline-interferon-alpha-2b to the best therapeutic current strategy&#xD;
      available based on phlebotomies and low dose acetylsalicylic acid (ASA) could improve the&#xD;
      efficacy of treatment of patients with PV at low risk of thrombosis (younger than 60 years&#xD;
      and without prior vascular events), in term of control of recommended level of hematocrit &lt;&#xD;
      45%, over a period of 12 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is an independent, investigator-generated, pragmatic trial including adult PV patients&#xD;
      (aged 18-60) diagnosed according to World Health Organization 2008 criteria within the last 3&#xD;
      years before inclusion, without history of thrombosis and younger than 60 years ('low risk'&#xD;
      patients).&#xD;
&#xD;
      Eligible patients are randomized to be treated with the best available therapy (recommended&#xD;
      for this risk class, standard arm) based on phlebotomy including administration of low-dose&#xD;
      (100 mg/daily) of acetylsalicylic acid (ASA, when there are not contraindications) OR&#xD;
      Pegylated Proline-Interferon alpha-2b (AOP2014) every 2 weeks in addition to the recommended&#xD;
      available regimen (experimental arm), for up to 12 months. The allocation of patients to&#xD;
      study arms is 1:1 and stratification at randomization will be performed according to age&#xD;
      category (&lt; 50 years old or &gt; 50 years old) and time from diagnosis (naϊve or non-naϊve).&#xD;
      Naive patients are defined as new cases coming to observation, diagnosed for the first time&#xD;
      just before study entry and never treated; non-naive patients are old cases (diagnosis not&#xD;
      older than 3 years before study entry) undergoing therapy with phlebotomy and/or low doses of&#xD;
      ASA.&#xD;
&#xD;
      Primary endpoint (PEp) is defined by the proportion (%) of patients who maintain the median&#xD;
      value of hematocrit (HCT) below 45% during 12 months of treatment in each arm, without&#xD;
      progression of disease and no need of any extra-protocol cytoreductive drug (responder&#xD;
      patients).&#xD;
&#xD;
      Secondary endpoints include evaluation of hematological and molecular response, histological&#xD;
      remission and safety profile of the protocol therapy.&#xD;
&#xD;
      Before randomization all patients undergo phlebotomies in order to reach an HCT below 45%.&#xD;
&#xD;
      After randomization, according to current common clinical practice the regimen of&#xD;
      phlebotomies must be selected accordingly to maintain the recommended level of HCT&lt; 45%. Once&#xD;
      normalization of the HCT has been achieved, blood counts at regular intervals (every 4 weeks)&#xD;
      will establish the frequency of future phlebotomies. Sufficient blood is recommended to be&#xD;
      removed in order maintain the hematocrit below 45%. Supplemental iron therapy should not be&#xD;
      administered.&#xD;
&#xD;
      All patients receive low-dose of ASA (100 mg/daily) as recommended by the current guidelines&#xD;
      for low-risk subjects with PV.&#xD;
&#xD;
      Patients allocated in the experimental group receive in addition a pre-filled auto-injection&#xD;
      pen for the subcutaneous auto-administration (into the abdominal skin or the thigh) of 100 µg&#xD;
      of Pegylated Proline-Interferon alpha-2b (AOP2014) once every 14 days.&#xD;
&#xD;
      Patient visits are scheduled every month (4 weeks) for 12 months to assess and perform a&#xD;
      reliable calculation of the primary end-point (% of patients with median HCT levels &lt;45%).&#xD;
&#xD;
      At each monthly visit a pre-filled auto-injection pen is delivered to the patients who have&#xD;
      been randomized in the experimental arm.&#xD;
&#xD;
      Assuming an expected drop-out rate of 12%, a total sample size of 150 patients (75 randomized&#xD;
      in each group) will be randomized to reject the null hypothesis that the proportion of&#xD;
      patients achieving the primary endpoint is 50% in favor of the alternative hypothesis that&#xD;
      this proportion is 75% when AOP2014 is added to the phlebotomy based- therapy, with a power&#xD;
      of 80% and an alpha error of 0.05 (two-tailed).&#xD;
&#xD;
      Two interim-analysis are planned when 50 and 100 of randomized patients have completed the 12&#xD;
      months study, respectively, in order to evaluate and supervise both safety and primary&#xD;
      endpoint. The Lan and DeMets (1983) spending function with O'Brien-Fleming type boundaries&#xD;
      will be employed to preserve the overall two-sided type I error rate for effectiveness at the&#xD;
      0.05 level, regardless of the timing of the analysis.&#xD;
&#xD;
      The results of the second interim analysis carried out at in April 2020 indicated a&#xD;
      significant higher efficacy of the experimental arm than standard arm. The composite primary&#xD;
      end-point was reached in 84% in patients of Ropeginterferon arm vs. 60% in standard arm&#xD;
      (p=0.008, Odds Ratio=3.5, 95% CI: 1.3-10.4). This result, according to the statistical&#xD;
      evaluation for futility and efficacy, reveals that , the null hypothesis is already been&#xD;
      proven with first 100 patients randomized and cannot change in the future when 150 patients&#xD;
      will enter the study. Therefore the data safety monitoring board and the steering committee&#xD;
      agree that the accrual of new patients can be interrupted with 127 patients included.&#xD;
&#xD;
      The primary endpoint assessment is performed after the completion of the first 12 months of&#xD;
      therapy for all subjects enrolled ('core study').&#xD;
&#xD;
      A period of 12 months is expected for completion of the enrolment / randomization phase. The&#xD;
      'core study' itself will take 12 months of treatment per patient.&#xD;
&#xD;
      Based on results from the 'core study' the extension phase will continue as follows:&#xD;
&#xD;
        1. After 12 month patients who meet the primary endpoint following either conventional or&#xD;
           experimental therapy will enter the extension phase and remain on their current regimen.&#xD;
&#xD;
        2. non-responders, not meeting the primary endpoint after 12 months of conventional therapy&#xD;
           will be switched to the experimental treatment.&#xD;
&#xD;
        3. non-responder, not meeting the primary endpoint after 12 months of experimental therapy&#xD;
           will be switched to conventional treatment.&#xD;
&#xD;
      This extension phase will last for another 12 months from the Last Visit Last Patient&#xD;
      included (LVLP) into the core study (matching cases 1 and 2 as defined above). Based on this,&#xD;
      the overall length of the study is expected to cover a period of 36 months from the First&#xD;
      Patient Included (FPI).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2, 2017</start_date>
  <completion_date type="Actual">March 31, 2023</completion_date>
  <primary_completion_date type="Actual">March 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who maintains the median value of HCT&lt; 45%, along 12 months, on number of patients randomized in each arm, per cent</measure>
    <time_frame>12 months</time_frame>
    <description>For each patient the median value of HCT percentage will be calculated from all measurements detected and reported every month (from baseline to 12-month visit or study end). A patient will be defined as responder (achieving PEp) when he maintains the median value of HCT &lt; 45%, after undergoing treatments according to this protocol, for up 12 months.&#xD;
A patient will be defined as non-responder (not achieving PEp) when&#xD;
Does not maintain the median value of HCT &lt; 45%, after undergoing treatments according to this protocol, for up 12 months, or&#xD;
Is in need of any additional chemotherapeutic and/or cytoreductive treatment aimed to manage disease due to disease progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median number of phlebotomies performed</measure>
    <time_frame>12 months, 24 months</time_frame>
    <description>The total number of phlebotomies will be calculated for each patients during 12 months of therapy (and then 24 months);&#xD;
Based on values obtained from point (1) in each arm-group of patients, the median number of phlebotomies performed in each therapy group will be calculated (and compared) after 12 and 24 months of therapy (or completion of the study)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients achieving hematological response (as defined below in 'Description') on number of patients randomized in each arm, per cent,</measure>
    <time_frame>12 months, 24 months</time_frame>
    <description>For each patient the median value of HCT (%), absolute white blood cells (WBCs) count and absolute platelets (PLTs) count will be calculated from all measurements detected and reported at least every month (from baseline to 12-month visit and then to 24-month visit/study completion). A patient will be defined as achieving hematological response when the median values of HCT &lt; 45%, WBCs count &lt; 10 x10*9/L and PLTs count &lt; 400 x10*9/L is observed after 12 months of therapy (or 24 months). The proportion of patients who maintains this response after 24 months (or study completion) will be calculated (and compared) in each arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion (rate per cent) of patients with not palpable spleen</measure>
    <time_frame>12 months, 24 months</time_frame>
    <description>The proportion (rate per cent) of patients with not palpable spleen will be calculated in each arm as the ratio of number of patients with resolution of splenomegaly or persistence of not palpable spleen at palpation with respect to baseline, on number of patients randomized in each arm, after 12 and 24 months (study completion) of therapy, per cent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Janus kinase-2 allele burden reduction or complete molecular remission</measure>
    <time_frame>12 months, 24 months</time_frame>
    <description>Quantitative Janus kinase-2 measurements (central lab facility) will be performed at baseline and after 12 months of therapy for all patients; Janus kinase-2 assessment will be performed also after 24 months for patients receiving interferon (experimental therapy). Reduction of allele burden in each patient (with respect to baseline) will be assessed according to Jovanovic et al, Leukemia 2013.&#xD;
The proportion (rate per cent) of patients with Janus kinase-2 allele burden reduction or remission will be calculated in each arm (and compared).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone marrow histological remission</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as presence of age-adjusted normocellularity and disappearance of trilinear hyperplasia, and absence of &gt;grade 1 reticulin fibrosis. It will be assessed in each patient and then the proportion (rate per cent) of patients with bone marrow histological remission will be calculated in each arm (and compared).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and frequence of thrombotic and hemorrhagic events occurred</measure>
    <time_frame>12 months, 24 months</time_frame>
    <description>The number of events will be recorded any time during the study in order to assess the frequency ,every 12 months and at completion of the study, and their incidence in each arm and whole population. Comparison between arms will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events occurred</measure>
    <time_frame>12 months, 24 months</time_frame>
    <description>Incidence, causality and intensity of clinical relevant adverse events will be assessed in each arm and compared all over the study.&#xD;
The rate of assigned treatment withdrawal due to any protocol drug-related toxicity occurred any time will be compared. Number of adverse events, expressed as frequency in each arm, will be calculated (as ratio of number of patient experiencing adverse on the the number of patients randomized in each arm) and compared</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>12 months, 24 months</time_frame>
    <description>Impact of PV and therapy on subjects will be evaluated through assessment of symptoms burden using Functional Assessment of cancer Therapy-Anaemia (FACT-An) and Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (MPN-SAF TSS) questionnaires, that will be administered to subjects trimonthly</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Polycythemia Vera</condition>
  <arm_group>
    <arm_group_label>Phlebotomies + ASA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional treatment based on phlebotomies and low dose (100 mg) of acetylsalicylic acid (ASA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phlebotomies + ASA + AOP2014</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional treatment based on phlebotomies, low dose (100 mg) of acetylsalicylic acid (ASA) plus the addition of 100 µg of Pegylated Proline-Interferon alpha-2b (AOP2014) once every 14 days (subcutaneously).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AOP2014</intervention_name>
    <description>AOP2014 will be supplied to the patients as pre-filled auto-injection pens, containing 250 µg of active drug (0.5 ml solution for injection). One pen may be used twice within a time period of 4 weeks. Hence investigators will provide one prefilled pen at every monthly visit. AOP2014 will be self-injected subcutaneously by patients once every 14 days at the single doses of 100 µg (0.2 ml).</description>
    <arm_group_label>Phlebotomies + ASA + AOP2014</arm_group_label>
    <other_name>Pegylated-Proline-Interferon α-2b, P1101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phlebotomies</intervention_name>
    <description>According to current common clinical practice the regimen must be selected accordingly to maintain the recommended level of HCT&lt; 45%. Once normalization of the hematocrit has been achieved, blood counts at regular intervals (every 4 weeks) will establish the frequency of future phlebotomies. Sufficient blood should be removed to maintain the hematocrit below 45%.</description>
    <arm_group_label>Phlebotomies + ASA</arm_group_label>
    <arm_group_label>Phlebotomies + ASA + AOP2014</arm_group_label>
    <other_name>blood removing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASA</intervention_name>
    <description>100 mg/daily of ASA is recommended (when there are not contraindications) according with current guidelines for this risk class of patients</description>
    <arm_group_label>Phlebotomies + ASA</arm_group_label>
    <arm_group_label>Phlebotomies + ASA + AOP2014</arm_group_label>
    <other_name>Acetylsalicylic Acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-60 years&#xD;
&#xD;
          -  Diagnosis of Polycythemia Vera according to World Health Organization 2016 criteria&#xD;
&#xD;
          -  Diagnosis of Polycythemia Vera including a recent bone marrow (BM) biopsy (performed&#xD;
             within 3 years prior randomization in the study) and never treated with cytoreductive&#xD;
             drugs&#xD;
&#xD;
          -  HCT&lt;45%&#xD;
&#xD;
          -  Ability and willingness to comply with all study requirements&#xD;
&#xD;
          -  Signed written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any previous well documented cardiovascular PV-related events (see Appendix 1 for&#xD;
             description)&#xD;
&#xD;
          -  Previous cytoreductive drugs&#xD;
&#xD;
          -  Known hypersensitivity or contraindications to the Investigational Medicinal Product&#xD;
             (Pegylated Proline-Interferon alpha-2b) including:&#xD;
&#xD;
        evidence of severe retinopathy (e.g. cytomegalovirus retinitis, macular degeneration) or&#xD;
        clinically relevant ophthalmological disorder (due to diabetes mellitus or hypertension);&#xD;
        thyroid dysfunction not adequately controlled; patients tested positively with&#xD;
        Thyroglobulin antibody and / or TPOAb at screening; documented autoimmune disease at&#xD;
        screening or in the medical history; history or presence of depression requiring treatment&#xD;
        with antidepressant; any risk of suicide at screening or previous suicide attempts;&#xD;
&#xD;
          -  Previous exposure to a non-pegylated or pegylated interferon α&#xD;
&#xD;
          -  Clinically relevant pulmonary infiltrates, pneumonia, and pneumonitis&#xD;
&#xD;
          -  Systemic infections, e.g. hepatitis B, hepatitis C, or HIV at screening&#xD;
&#xD;
          -  Significant liver (AST or alanine aminotransferase &gt; 2.5 times ULN) or renal disease&#xD;
             (creatinine &gt; 2 mg/ml)&#xD;
&#xD;
          -  Presence of any life-threatening condition or of any disease (e.g. cancer) that is&#xD;
             likely to significantly shorten life expectancy&#xD;
&#xD;
          -  History of active substance or alcohol abuse within the last year&#xD;
&#xD;
          -  Any condition that in the opinion of the investigator would jeopardize the evaluation&#xD;
             of efficacy or safety or be associated with poor adherence to the protocol&#xD;
&#xD;
          -  Pregnant or lactating women and women*/men of childbearing potential who are not using&#xD;
             or are not willing to use any effective means of contraception (i.e. sexual&#xD;
             abstinence, hormonal contraceptive, intra-uterine device, barrier method such as&#xD;
             diaphragms or condoms, surgical methods).&#xD;
&#xD;
               -  Pregnancy test will be performed in order to ascertain negativity of human&#xD;
                  chorionic gonadotropin (β-hCG) test and confirm that childbearing women are not&#xD;
                  pregnant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tiziano Barbui, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Fondazione per la Ricerca Ospedale Maggiore di Bergamo (FROM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.O. Ematologia, Ospedale Casa Sollievo della Sofferenza Istituto di Ricovero e Cura a Carattere Scientifico</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>(FG) Puglia</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II di Napoli</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia Policlinico S. Orsola - Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>Emilia Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica, Azienda Ospedaliero-Universitaria &quot;Santa Maria della Misericordia&quot;</name>
      <address>
        <city>Udine</city>
        <state>Friuli Venezia Giulia</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSC Ematologia, Fondazione Policlinico Universitario &quot;Agostino Gemelli&quot;Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia, ASST Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <state>Lombardia</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Oncoematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia ASST, Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia, ASST di MONZA - Ospedale San Gerardo di Monza</name>
      <address>
        <city>Monza</city>
        <state>Lombardia</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia, Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia, Ospedale di Circolo e Fondazione Macchi Varese</name>
      <address>
        <city>Varese</city>
        <state>Lombardia</state>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia Azienda Ospedaliera S. Croce e Carle Cuneo</name>
      <address>
        <city>Cuneo</city>
        <state>Piemonte</state>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCDU Ematologia, A.O.U. Maggiore della Carità</name>
      <address>
        <city>Novara</city>
        <state>Piemonte</state>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia, AOU- Presidio Ospedaliero Molinette</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia con Trapianto, Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari</name>
      <address>
        <city>Bari</city>
        <state>Puglia</state>
        <zip>70120</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa di Emostasi Azienda Ospedaliero-Universitario &quot;Policlinico Vittorio-Emanuele - Presidio Ospedaliero Ferrarotto</name>
      <address>
        <city>Catania</city>
        <state>Sicilia</state>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia, Azienda Ospedaliera Universitaria Policlinico &quot;G. Martino&quot;</name>
      <address>
        <city>Messina</city>
        <state>Sicilia</state>
        <zip>98100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia Azienda Ospedaliera Universitaria Policlinico &quot;Paolo Giaccone&quot; Palermo</name>
      <address>
        <city>Palermo</city>
        <state>Sicilia</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOD Ematologia AUOC Azienda Ospedaliero-Universitaria &quot;Careggi&quot;</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Medica I Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia, Ospedale Borgo Roma</name>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia, Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <state>Veneto</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005 Apr 28;352(17):1779-90. doi: 10.1056/NEJMoa051113.</citation>
    <PMID>15858187</PMID>
  </reference>
  <reference>
    <citation>Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ, Gilliland DG, Lodish HF, Green AR. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007 Feb 1;356(5):459-68. doi: 10.1056/NEJMoa065202.</citation>
    <PMID>17267906</PMID>
  </reference>
  <reference>
    <citation>Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F, Kiladjian JJ, McMullin MF, Ruggeri M, Besses C, Vannucchi AM, Lippert E, Gisslinger H, Rumi E, Lehmann T, Ortmann CA, Pietra D, Pascutto C, Haferlach T, Cazzola M. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011 Mar 10;117(10):2813-6. doi: 10.1182/blood-2010-11-316810. Epub 2011 Jan 11.</citation>
    <PMID>21224469</PMID>
  </reference>
  <reference>
    <citation>Vannucchi AM, Rotunno G, Bartalucci N, Raugei G, Carrai V, Balliu M, Mannarelli C, Pacilli A, Calabresi L, Fjerza R, Pieri L, Bosi A, Manfredini R, Guglielmelli P. Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia. 2014 Sep;28(9):1811-8. doi: 10.1038/leu.2014.100. Epub 2014 Mar 12.</citation>
    <PMID>24618731</PMID>
  </reference>
  <reference>
    <citation>Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kroger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A; European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011 Feb 20;29(6):761-70. doi: 10.1200/JCO.2010.31.8436. Epub 2011 Jan 4.</citation>
    <PMID>21205761</PMID>
  </reference>
  <reference>
    <citation>Najean Y, Rain JD. The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Semin Hematol. 1997 Jan;34(1):6-16. No abstract available.</citation>
    <PMID>9025157</PMID>
  </reference>
  <reference>
    <citation>Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. &quot;Leukemia and Hematosarcoma&quot; Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). Br J Cancer. 1981 Jul;44(1):75-80. doi: 10.1038/bjc.1981.150.</citation>
    <PMID>7020738</PMID>
  </reference>
  <reference>
    <citation>Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005 Apr 1;23(10):2224-32. doi: 10.1200/JCO.2005.07.062. Epub 2005 Feb 14.</citation>
    <PMID>15710945</PMID>
  </reference>
  <reference>
    <citation>Barosi G, Vannucchi AM, De Stefano V, Pane F, Passamonti F, Rambaldi A, Saglio G, Barbui T, Tura S. Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper. Leuk Res. 2014 Feb;38(2):155-60. doi: 10.1016/j.leukres.2013.09.008. Epub 2013 Sep 19.</citation>
    <PMID>24378116</PMID>
  </reference>
  <reference>
    <citation>Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Vannucchi AM, Besses C, Gisslinger H, Samuelsson J, Verstovsek S, Hoffman R, Pardanani A, Cervantes F, Tefferi A, Barbui T. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013 Jun 6;121(23):4778-81. doi: 10.1182/blood-2013-01-478891. Epub 2013 Apr 16.</citation>
    <PMID>23591792</PMID>
  </reference>
  <reference>
    <citation>Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8.</citation>
    <PMID>23216616</PMID>
  </reference>
  <reference>
    <citation>Gisslinger H, Ludwig H, Linkesch W, Chott A, Fritz E, Radaszkiewicz T. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet. 1989 Mar 25;1(8639):634-7. doi: 10.1016/s0140-6736(89)92142-9.</citation>
    <PMID>2564458</PMID>
  </reference>
  <reference>
    <citation>Tefferi A, Hudgens S, Mesa R, Gale RP, Verstovsek S, Passamonti F, Cervantes F, Rivera C, Tencer T, Khan ZM. Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. Clin Ther. 2014 Apr 1;36(4):560-6. doi: 10.1016/j.clinthera.2014.02.016. Epub 2014 Mar 14.</citation>
    <PMID>24636526</PMID>
  </reference>
  <reference>
    <citation>Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernandez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012 Nov 20;30(33):4098-103. doi: 10.1200/JCO.2012.42.3863. Epub 2012 Oct 15. Erratum In: J Clin Oncol. 2012 Dec 20;30(36):4590. Ferarri, Maria L [corrected to Ferrari, Maria L].</citation>
    <PMID>23071245</PMID>
  </reference>
  <reference>
    <citation>Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood. 2009 Jul 23;114(4):759-63. doi: 10.1182/blood-2009-02-206797. Epub 2009 Apr 16.</citation>
    <PMID>19372254</PMID>
  </reference>
  <reference>
    <citation>Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011 May 5;117(18):4706-15. doi: 10.1182/blood-2010-08-258772. Epub 2011 Mar 9.</citation>
    <PMID>21389325</PMID>
  </reference>
  <reference>
    <citation>Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, Bellucci S, Grandchamp B, Chomienne C, Fenaux P. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008 Oct 15;112(8):3065-72. doi: 10.1182/blood-2008-03-143537. Epub 2008 Jul 23.</citation>
    <PMID>18650451</PMID>
  </reference>
  <reference>
    <citation>Quintas-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek S. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. Blood. 2013 Aug 8;122(6):893-901. doi: 10.1182/blood-2012-07-442012. Epub 2013 Jun 19.</citation>
    <PMID>23782935</PMID>
  </reference>
  <reference>
    <citation>Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, Pallisgaard N, Maroc N, Hermouet S, Nickless G, Guglielmelli P, van der Reijden BA, Jansen JH, Alpermann T, Schnittger S, Bench A, Tobal K, Wilkins B, Cuthill K, McLornan D, Yeoman K, Akiki S, Bryon J, Jeffries S, Jones A, Percy MJ, Schwemmers S, Gruender A, Kelley TW, Reading S, Pancrazzi A, McMullin MF, Pahl HL, Cross NC, Harrison CN, Prchal JT, Chomienne C, Kiladjian JJ, Barbui T, Grimwade D. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&amp;MPNr-EuroNet (COST action BM0902) study. Leukemia. 2013 Oct;27(10):2032-9. doi: 10.1038/leu.2013.219. Epub 2013 Jul 17.</citation>
    <PMID>23860450</PMID>
  </reference>
  <verification_date>August 2023</verification_date>
  <study_first_submitted>November 3, 2016</study_first_submitted>
  <study_first_submitted_qc>December 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2016</study_first_posted>
  <last_update_submitted>August 2, 2023</last_update_submitted>
  <last_update_submitted_qc>August 2, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>low risk of thrombosis</keyword>
  <keyword>Interferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan has been defined yet about sharing of IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03003325
org study id: Low-PV
nct id: NCT03003325
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
The Low-PV study is a multicenter, phase II, randomized trial aimed to assess whether the
      addition of Pegylated Proline-interferon-alpha-2b to the best therapeutic current strategy
      available based on phlebotomies and low dose acetylsalicylic acid (ASA) could improve the
      efficacy of treatment of patients with PV at low risk of thrombosis (younger than 60 years
      and without prior vascular events), in term of control of recommended level of hematocrit <
      45%, over a period of 12 months.
It is an independent, investigator-generated, pragmatic trial including adult PV patients
      (aged 18-60) diagnosed according to World Health Organization 2008 criteria within the last 3
      years before inclusion, without history of thrombosis and younger than 60 years ('low risk'
      patients).

      Eligible patients are randomized to be treated with the best available therapy (recommended
      for this risk class, standard arm) based on phlebotomy including administration of low-dose
      (100 mg/daily) of acetylsalicylic acid (ASA, when there are not contraindications) OR
      Pegylated Proline-Interferon alpha-2b (AOP2014) every 2 weeks in addition to the recommended
      available regimen (experimental arm), for up to 12 months. The allocation of patients to
      study arms is 1:1 and stratification at randomization will be performed according to age
      category (< 50 years old or > 50 years old) and time from diagnosis (naϊve or non-naϊve).
      Naive patients are defined as new cases coming to observation, diagnosed for the first time
      just before study entry and never treated; non-naive patients are old cases (diagnosis not
      older than 3 years before study entry) undergoing therapy with phlebotomy and/or low doses of
      ASA.

      Primary endpoint (PEp) is defined by the proportion (%) of patients who maintain the median
      value of hematocrit (HCT) below 45% during 12 months of treatment in each arm, without
      progression of disease and no need of any extra-protocol cytoreductive drug (responder
      patients).

      Secondary endpoints include evaluation of hematological and molecular response, histological
      remission and safety profile of the protocol therapy.

      Before randomization all patients undergo phlebotomies in order to reach an HCT below 45%.

      After randomization, according to current common clinical practice the regimen of
      phlebotomies must be selected accordingly to maintain the recommended level of HCT< 45%. Once
      normalization of the HCT has been achieved, blood counts at regular intervals (every 4 weeks)
      will establish the frequency of future phlebotomies. Sufficient blood is recommended to be
      removed in order maintain the hematocrit below 45%. Supplemental iron therapy should not be
      administered.

      All patients receive low-dose of ASA (100 mg/daily) as recommended by the current guidelines
      for low-risk subjects with PV.

      Patients allocated in the experimental group receive in addition a pre-filled auto-injection
      pen for the subcutaneous auto-administration (into the abdominal skin or the thigh) of 100 µg
      of Pegylated Proline-Interferon alpha-2b (AOP2014) once every 14 days.

      Patient visits are scheduled every month (4 weeks) for 12 months to assess and perform a
      reliable calculation of the primary end-point (% of patients with median HCT levels <45%).

      At each monthly visit a pre-filled auto-injection pen is delivered to the patients who have
      been randomized in the experimental arm.

      Assuming an expected drop-out rate of 12%, a total sample size of 150 patients (75 randomized
      in each group) will be randomized to reject the null hypothesis that the proportion of
      patients achieving the primary endpoint is 50% in favor of the alternative hypothesis that
      this proportion is 75% when AOP2014 is added to the phlebotomy based- therapy, with a power
      of 80% and an alpha error of 0.05 (two-tailed).

      Two interim-analysis are planned when 50 and 100 of randomized patients have completed the 12
      months study, respectively, in order to evaluate and supervise both safety and primary
      endpoint. The Lan and DeMets (1983) spending function with O'Brien-Fleming type boundaries
      will be employed to preserve the overall two-sided type I error rate for effectiveness at the
      0.05 level, regardless of the timing of the analysis.

      The results of the second interim analysis carried out at in April 2020 indicated a
      significant higher efficacy of the experimental arm than standard arm. The composite primary
      end-point was reached in 84% in patients of Ropeginterferon arm vs. 60% in standard arm
      (p=0.008, Odds Ratio=3.5, 95% CI: 1.3-10.4). This result, according to the statistical
      evaluation for futility and efficacy, reveals that , the null hypothesis is already been
      proven with first 100 patients randomized and cannot change in the future when 150 patients
      will enter the study. Therefore the data safety monitoring board and the steering committee
      agree that the accrual of new patients can be interrupted with 127 patients included.

      The primary endpoint assessment is performed after the completion of the first 12 months of
      therapy for all subjects enrolled ('core study').

      A period of 12 months is expected for completion of the enrolment / randomization phase. The
      'core study' itself will take 12 months of treatment per patient.

      Based on results from the 'core study' the extension phase will continue as follows:

        1. After 12 month patients who meet the primary endpoint following either conventional or
           experimental therapy will enter the extension phase and remain on their current regimen.

        2. non-responders, not meeting the primary endpoint after 12 months of conventional therapy
           will be switched to the experimental treatment.

        3. non-responder, not meeting the primary endpoint after 12 months of experimental therapy
           will be switched to conventional treatment.

      This extension phase will last for another 12 months from the Last Visit Last Patient
      included (LVLP) into the core study (matching cases 1 and 2 as defined above). Based on this,
      the overall length of the study is expected to cover a period of 36 months from the First
      Patient Included (FPI).
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Number of patients who maintains the median value of HCT< 45%, along 12 months, on number of patients randomized in each arm, per cent
time frame: 12 months
description: For each patient the median value of HCT percentage will be calculated from all measurements detected and reported every month (from baseline to 12-month visit or study end). A patient will be defined as responder (achieving PEp) when he maintains the median value of HCT < 45%, after undergoing treatments according to this protocol, for up 12 months.
A patient will be defined as non-responder (not achieving PEp) when
Does not maintain the median value of HCT < 45%, after undergoing treatments according to this protocol, for up 12 months, or
Is in need of any additional chemotherapeutic and/or cytoreductive treatment aimed to manage disease due to disease progression.
measure: Median number of phlebotomies performed
time frame: 12 months, 24 months
description: The total number of phlebotomies will be calculated for each patients during 12 months of therapy (and then 24 months);
Based on values obtained from point (1) in each arm-group of patients, the median number of phlebotomies performed in each therapy group will be calculated (and compared) after 12 and 24 months of therapy (or completion of the study)
measure: Number of patients achieving hematological response (as defined below in 'Description') on number of patients randomized in each arm, per cent,
time frame: 12 months, 24 months
description: For each patient the median value of HCT (%), absolute white blood cells (WBCs) count and absolute platelets (PLTs) count will be calculated from all measurements detected and reported at least every month (from baseline to 12-month visit and then to 24-month visit/study completion). A patient will be defined as achieving hematological response when the median values of HCT < 45%, WBCs count < 10 x10*9/L and PLTs count < 400 x10*9/L is observed after 12 months of therapy (or 24 months). The proportion of patients who maintains this response after 24 months (or study completion) will be calculated (and compared) in each arm.
measure: Proportion (rate per cent) of patients with not palpable spleen
time frame: 12 months, 24 months
description: The proportion (rate per cent) of patients with not palpable spleen will be calculated in each arm as the ratio of number of patients with resolution of splenomegaly or persistence of not palpable spleen at palpation with respect to baseline, on number of patients randomized in each arm, after 12 and 24 months (study completion) of therapy, per cent.
measure: Janus kinase-2 allele burden reduction or complete molecular remission
time frame: 12 months, 24 months
description: Quantitative Janus kinase-2 measurements (central lab facility) will be performed at baseline and after 12 months of therapy for all patients; Janus kinase-2 assessment will be performed also after 24 months for patients receiving interferon (experimental therapy). Reduction of allele burden in each patient (with respect to baseline) will be assessed according to Jovanovic et al, Leukemia 2013.
The proportion (rate per cent) of patients with Janus kinase-2 allele burden reduction or remission will be calculated in each arm (and compared).
measure: Bone marrow histological remission
time frame: 24 months
description: Defined as presence of age-adjusted normocellularity and disappearance of trilinear hyperplasia, and absence of >grade 1 reticulin fibrosis. It will be assessed in each patient and then the proportion (rate per cent) of patients with bone marrow histological remission will be calculated in each arm (and compared).
measure: Incidence and frequence of thrombotic and hemorrhagic events occurred
time frame: 12 months, 24 months
description: The number of events will be recorded any time during the study in order to assess the frequency ,every 12 months and at completion of the study, and their incidence in each arm and whole population. Comparison between arms will be performed.
measure: Number of adverse events occurred
time frame: 12 months, 24 months
description: Incidence, causality and intensity of clinical relevant adverse events will be assessed in each arm and compared all over the study.
The rate of assigned treatment withdrawal due to any protocol drug-related toxicity occurred any time will be compared. Number of adverse events, expressed as frequency in each arm, will be calculated (as ratio of number of patient experiencing adverse on the the number of patients randomized in each arm) and compared
measure: Quality of Life (QoL)
time frame: 12 months, 24 months
description: Impact of PV and therapy on subjects will be evaluated through assessment of symptoms burden using Functional Assessment of cancer Therapy-Anaemia (FACT-An) and Myeloproliferative Neoplasm Symptom Assessment Form total symptom score (MPN-SAF TSS) questionnaires, that will be administered to subjects trimonthly
arm group label: Phlebotomies + ASA
arm group type: Active Comparator
description: Conventional treatment based on phlebotomies and low dose (100 mg) of acetylsalicylic acid (ASA)
arm group label: Phlebotomies + ASA + AOP2014
arm group type: Experimental
description: Conventional treatment based on phlebotomies, low dose (100 mg) of acetylsalicylic acid (ASA) plus the addition of 100 µg of Pegylated Proline-Interferon alpha-2b (AOP2014) once every 14 days (subcutaneously).
intervention type: Drug
intervention name: AOP2014
description: AOP2014 will be supplied to the patients as pre-filled auto-injection pens, containing 250 µg of active drug (0.5 ml solution for injection). One pen may be used twice within a time period of 4 weeks. Hence investigators will provide one prefilled pen at every monthly visit. AOP2014 will be self-injected subcutaneously by patients once every 14 days at the single doses of 100 µg (0.2 ml).
arm group label: Phlebotomies + ASA + AOP2014
other name: Pegylated-Proline-Interferon α-2b, P1101
intervention type: Procedure
intervention name: Phlebotomies
description: According to current common clinical practice the regimen must be selected accordingly to maintain the recommended level of HCT< 45%. Once normalization of the hematocrit has been achieved, blood counts at regular intervals (every 4 weeks) will establish the frequency of future phlebotomies. Sufficient blood should be removed to maintain the hematocrit below 45%.
arm group label: Phlebotomies + ASA
arm group label: Phlebotomies + ASA + AOP2014
other name: blood removing
intervention type: Drug
intervention name: ASA
description: 100 mg/daily of ASA is recommended (when there are not contraindications) according with current guidelines for this risk class of patients
arm group label: Phlebotomies + ASA
arm group label: Phlebotomies + ASA + AOP2014
other name: Acetylsalicylic Acid
criteria: 
gender: All
minimum age: 18 Years
maximum age: 60 Years
healthy volunteers: No
last name: Tiziano Barbui, Professor
role: Study Chair
affiliation: Fondazione per la Ricerca Ospedale Maggiore di Bergamo (FROM)
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Italy
citation: Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005 Apr 28;352(17):1779-90. doi: 10.1056/NEJMoa051113.
PMID: 15858187
citation: Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ, Gilliland DG, Lodish HF, Green AR. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007 Feb 1;356(5):459-68. doi: 10.1056/NEJMoa065202.
PMID: 17267906
citation: Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F, Kiladjian JJ, McMullin MF, Ruggeri M, Besses C, Vannucchi AM, Lippert E, Gisslinger H, Rumi E, Lehmann T, Ortmann CA, Pietra D, Pascutto C, Haferlach T, Cazzola M. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011 Mar 10;117(10):2813-6. doi: 10.1182/blood-2010-11-316810. Epub 2011 Jan 11.
PMID: 21224469
citation: Vannucchi AM, Rotunno G, Bartalucci N, Raugei G, Carrai V, Balliu M, Mannarelli C, Pacilli A, Calabresi L, Fjerza R, Pieri L, Bosi A, Manfredini R, Guglielmelli P. Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia. 2014 Sep;28(9):1811-8. doi: 10.1038/leu.2014.100. Epub 2014 Mar 12.
PMID: 24618731
citation: Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kroger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A; European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011 Feb 20;29(6):761-70. doi: 10.1200/JCO.2010.31.8436. Epub 2011 Jan 4.
PMID: 21205761
citation: Najean Y, Rain JD. The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Semin Hematol. 1997 Jan;34(1):6-16. No abstract available.
PMID: 9025157
citation: Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). Br J Cancer. 1981 Jul;44(1):75-80. doi: 10.1038/bjc.1981.150.
PMID: 7020738
citation: Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005 Apr 1;23(10):2224-32. doi: 10.1200/JCO.2005.07.062. Epub 2005 Feb 14.
PMID: 15710945
citation: Barosi G, Vannucchi AM, De Stefano V, Pane F, Passamonti F, Rambaldi A, Saglio G, Barbui T, Tura S. Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper. Leuk Res. 2014 Feb;38(2):155-60. doi: 10.1016/j.leukres.2013.09.008. Epub 2013 Sep 19.
PMID: 24378116
citation: Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Vannucchi AM, Besses C, Gisslinger H, Samuelsson J, Verstovsek S, Hoffman R, Pardanani A, Cervantes F, Tefferi A, Barbui T. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013 Jun 6;121(23):4778-81. doi: 10.1182/blood-2013-01-478891. Epub 2013 Apr 16.
PMID: 23591792
citation: Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8.
PMID: 23216616
citation: Gisslinger H, Ludwig H, Linkesch W, Chott A, Fritz E, Radaszkiewicz T. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet. 1989 Mar 25;1(8639):634-7. doi: 10.1016/s0140-6736(89)92142-9.
PMID: 2564458
citation: Tefferi A, Hudgens S, Mesa R, Gale RP, Verstovsek S, Passamonti F, Cervantes F, Rivera C, Tencer T, Khan ZM. Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. Clin Ther. 2014 Apr 1;36(4):560-6. doi: 10.1016/j.clinthera.2014.02.016. Epub 2014 Mar 14.
PMID: 24636526
citation: Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernandez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012 Nov 20;30(33):4098-103. doi: 10.1200/JCO.2012.42.3863. Epub 2012 Oct 15. Erratum In: J Clin Oncol. 2012 Dec 20;30(36):4590. Ferarri, Maria L [corrected to Ferrari, Maria L].
PMID: 23071245
citation: Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood. 2009 Jul 23;114(4):759-63. doi: 10.1182/blood-2009-02-206797. Epub 2009 Apr 16.
PMID: 19372254
citation: Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011 May 5;117(18):4706-15. doi: 10.1182/blood-2010-08-258772. Epub 2011 Mar 9.
PMID: 21389325
citation: Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, Bellucci S, Grandchamp B, Chomienne C, Fenaux P. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008 Oct 15;112(8):3065-72. doi: 10.1182/blood-2008-03-143537. Epub 2008 Jul 23.
PMID: 18650451
citation: Quintas-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek S. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. Blood. 2013 Aug 8;122(6):893-901. doi: 10.1182/blood-2012-07-442012. Epub 2013 Jun 19.
PMID: 23782935
citation: Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, Pallisgaard N, Maroc N, Hermouet S, Nickless G, Guglielmelli P, van der Reijden BA, Jansen JH, Alpermann T, Schnittger S, Bench A, Tobal K, Wilkins B, Cuthill K, McLornan D, Yeoman K, Akiki S, Bryon J, Jeffries S, Jones A, Percy MJ, Schwemmers S, Gruender A, Kelley TW, Reading S, Pancrazzi A, McMullin MF, Pahl HL, Cross NC, Harrison CN, Prchal JT, Chomienne C, Kiladjian JJ, Barbui T, Grimwade D. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia. 2013 Oct;27(10):2032-9. doi: 10.1038/leu.2013.219. Epub 2013 Jul 17.
PMID: 23860450
responsible party type: Sponsor
mesh term: Polycythemia Vera
mesh term: Polycythemia
mesh term: Aspirin
mesh term: Interferons
sharing ipd: No
ipd description: No plan has been defined yet about sharing of IPD